Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s68, 2022. DOI: 10.25251/skin.6.supp.68. Disponível em: https://skin.dermsquared.com/skin/article/view/1824. Acesso em: 17 may. 2025.